Archive

  • Matching adjustment details challenge UK insurers

    22 April 2015

    The matching adjustment is currently the biggest issue for UK insurer asset portfolios before Solvency II comes into force next year. Among the key issues are equity release, FX hedges and collateral. Sarfraz Thind reports

  • Unit-linked portfolios under Solvency II could offer significant capital benefits

    03 February 2015

    The matching requirements for unit-linked assets and liabilities offer the possibility of both stabilising the economic balance sheet and enhancing the solvency position, argue Sinéad Clarke, Kevin Manning, Scott Mitchell and Eamonn Phelan

  • Revisiting replicating portfolios

    14 November 2014

    The benefits of using orthogonal calibration with principal component analysis of the candidate assets when calibrating a replicating portfolio are explained by Alexey Botvinnik, Dr Mario Hoerig, Dr Florian Ketterer, Alexander Tazov and Florian Wechsung

  • Optimising Solvency II capital through investment strategy

    12 September 2014

    Insurers should consider their overall investment strategy holistically to minimise SCR capital charges

  • European insurers see embedded values rise

    17 July 2014

    New business aiding recovery says Milliman

  • Annuity changes put corporate bonds under pressure

    23 April 2014

    Revisions to the UK's legislation around annuities is causing insurers to rethink investment strategies. Hardeep Dhillon examines the impact on sterling capital markets and demand for assets

  • Derivatives used for hedging by two out of three life insurers

    14 April 2014

    Interest-rate, equity and currency risks are the main ones hedged, Milliman survey finds

  • Hopes build for better treatment of infrastructure investment under Solvency II

    27 September 2013

    Infrastructure investments provide a great match for insurers' liabilities, but Solvency II's crude view of the investment risk means money is not flowing as fast as it could. Milliman and JP Morgan Asset Management set out the justification for a review